Tulobuterol (Bremax)
Tulobuterol
Abbott Laboratories S.A. (Pty) Ltd
Registration
- Applicant
- Abbott Laboratories S.A. (Pty) Ltd
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Bremax tablets EACH TABLET CONTAINS TULOBUTEROL HYDROCHLORIDE 2,0 mg | Tablets | V0265V/10.2/265 | Registered | Not determined | None |
| Bremax syrup* EACH 5 ml SYRUP CONTAINS TULOBUTEROL HYDROCHLORIDE 1,0 mg | Syrup | V0266V/10.1/266 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S3: Tulobuterol
- when contained in respirator solutions.
Consolidated Schedules 06 July 2026, line 4364
S2: Tulobuterol
- except when contained in respirator solutions.
Consolidated Schedules 06 July 2026, line 2749
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
2-(tert-Butylamino)-1-(2-chlorophenyl)ethanol
Drag to rotate. Structure from PubChem CID 5606.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.